A Phase 2a Open Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous ANX005 in Subjects with, or at Risk for, Manifest Huntington's Disease
Clinical Trial Grant
Administered By
Neurology, Movement Disorders
Awarded By
Annexon Biosciences
Start Date
August 6, 2020
End Date
December 31, 2022
Administered By
Neurology, Movement Disorders
Awarded By
Annexon Biosciences
Start Date
August 6, 2020
End Date
December 31, 2022